מתוך medicontext.co.il
WESTPORT, CT (Reuters Health) – Attenuating eosinophilic airway inflammation in atopic asthma patients reduces CD14 expression by monocytic cells and results in a decreased neutrophil response to lipopolysaccharide (LPS) challenge.
The current findings further support the hypothesis that atopic inflammation alters CD14-associated responses to LPS challenge, Dr. Neil E. Alexis and Dr. David B. Peden note in the October issue of the Journal of Allergy and Clinical Immunology.
At the University of North Carolina at Chapel Hill, they performed a randomized crossover study of fluticasone propionate versus placebo in 12 patients with atopic asthma. During each phase of the study, the subjects were treated for 2 weeks and then challenged with inhaled LPS. Sputum samples collected after the fluticasone and placebo phases were analyzed for inflammatory cells and for CD14 expression by monocytic cells.
Prior to LPS challenge, the researchers found that fluticasone treatment was associated with a significant reduction in the number of airway eosinophils (p = 0.04) and in mCD14 expression (p = 0.03). However, fluticasone treatment did not decrease the number of neutrophils present.
Six hours after LPS challenge, fluticasone treatment was linked to a significant reduction in airway neutrophils and in mCD14 expression compared with placebo (p = 0.04), the investigators state.
"Our data indicate that fluticasone, through its action on airway atopic inflammation as well as its action, either direct or indirect, on CD14, decreases the response of an individual with allergic asthma to inhaled LPS."
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!